- Home
- CGBD vs KURA Comparison
CGBD vs KURA Comparison
Compare CGBD & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- KURA
- Stock Information
- Founded
- CGBD 2012
- KURA 2014
- Country
- CGBD United States
- KURA United States
- Employees
- CGBD N/A
- KURA N/A
- Industry
- CGBD Finance: Consumer Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGBD Finance
- KURA Health Care
- Exchange
- CGBD Nasdaq
- KURA Nasdaq
- Market Cap
- CGBD 881.7M
- KURA 793.2M
- IPO Year
- CGBD 2017
- KURA N/A
- Fundamental
- Price
- CGBD $18.00
- KURA $9.01
- Analyst Decision
- CGBD Hold
- KURA Strong Buy
- Analyst Count
- CGBD 4
- KURA 10
- Target Price
- CGBD $16.25
- KURA $30.13
- AVG Volume (30 Days)
- CGBD 228.5K
- KURA 2.5M
- Earning Date
- CGBD 11-05-2024
- KURA 11-07-2024
- Dividend Yield
- CGBD 2.67%
- KURA N/A
- EPS Growth
- CGBD 29.39
- KURA N/A
- EPS
- CGBD 1.72
- KURA N/A
- Revenue
- CGBD $238,921,000.00
- KURA N/A
- Revenue This Year
- CGBD N/A
- KURA N/A
- Revenue Next Year
- CGBD $4.63
- KURA $106.66
- P/E Ratio
- CGBD $10.44
- KURA N/A
- Revenue Growth
- CGBD 1.68
- KURA N/A
- 52 Week Low
- CGBD $14.76
- KURA $8.85
- 52 Week High
- CGBD $18.74
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- CGBD 65.73
- KURA 22.05
- Support Level
- CGBD $17.61
- KURA $8.85
- Resistance Level
- CGBD $18.19
- KURA $10.02
- Average True Range (ATR)
- CGBD 0.32
- KURA 0.48
- MACD
- CGBD 0.04
- KURA 0.08
- Stochastic Oscillator
- CGBD 72.03
- KURA 6.30
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.